Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
L M Spring, S M Tolaney, G Fell...
https://pubmed.ncbi.nlm.nih.gov/38092228/Actively Recruiting
Led by Massachusetts General Hospital · Updated on 2026-07-17
239
Participants Needed
5
Research Sites
52 weeks
Total Duration
Researchers are evaluating sacituzumab govitecan for people with localized triple negative breast cancer TNBC in this Phase II clinical trial. The study aims to assess the safety and effectiveness of this investigational drug, alone or combined with pembrolizumab, in treating this specific type of breast cancer. This trial is part of an umbrella study exploring different treatment options for breast cancer patients, including future arms for hormone receptor positive and inflammatory breast cancers. Participants will receive sacituzumab govitecan through intravenous infusions on two days every 21-day cycle, for up to four cycles approximately 12 weeks. After completing the sacituzumab govitecan monotherapy cohort, a combination therapy cohort with pembrolizumab will open. Some participants may also receive standard chemotherapy afterward, based on their doctors decision. The study includes screening, treatment, evaluations, and follow-up visits. During the study, participants will undergo various assessments including biopsies, laboratory tests, and evaluations to monitor response and safety. Researchers will measure outcomes such as the pathological complete response rate at 12 weeks, disease-free survival, overall survival, quality of life, and treatment-related side effects. The total participant involvement may last up to 36 months for long-term monitoring of outcomes and safety.
CONDITIONS
Sacituzumab Govitecan In TNBC
L
Laura Spring, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts General Hospital
Lead Sponsor
Gilead Sciences
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Sacituzumab Govitecan (Monotherapy Cohort) | Sacituzumab Govitecan Plus Pembrolizumab (Combination Cohort) |
|---|---|---|
| What it is | Monotherapy cohort: Sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2 on tumor cells, administered by intravenous infusion. | Combination cohort: Sacituzumab govitecan plus pembrolizumab (a PD-1 inhibitor immune checkpoint blocker), both administered intravenously. |
| Role in this trial | Assesses sacituzumab govitecan as a single-agent neoadjuvant therapy in participants with previously untreated triple-negative breast cancer. | Evaluates the combination of sacituzumab govitecan and pembrolizumab for potential additive or synergistic benefit in this patient group. |
| Primary use | Investigational neoadjuvant treatment for adults with previously untreated localized triple-negative breast cancer. | Experimental neoadjuvant treatment designed to test the combination approach in the same eligible breast cancer setting. |
| How it is given or performed | Sacituzumab govitecan is given by intravenous infusion on two days per 21-day cycle, for four cycles. | Sacituzumab govitecan is administered by IV infusion alongside pembrolizumab, both on a 21-day cycle for four cycles. |
| Evidence status | Active investigation is underway; recent non-randomized studies (such as the NeoSTAR trial) report promising responses with neoadjuvant sacituzumab govitecan in localized triple-negative breast cancer, but clinical benefit and definitive outcomes in the preoperative setting remain under study. | This combination is currently under clinical investigation; no published outcome data are available as of the latest referenced NeoSTAR publication, and the effect of adding pembrolizumab to sacituzumab govitecan in this setting is not yet established. |
| Important limitations | Non-randomized cohort design means outcomes are not compared to standard chemotherapy or other established neoadjuvant regimens; mature survival results and head-to-head effectiveness data are not yet available. | No randomized control group or direct comparison to standard chemotherapy in the neoadjuvant setting; combination efficacy and safety require further, larger randomized trials. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 weeks
Participants receive sacituzumab govitecan intravenously on two days every 21-day cycle, for up to four cycles. Some may also receive pembrolizumab once per cycle depending on the study group. Additional standard chemotherapy may follow based on doctor's choice.
Treatments given every 21 days for 4 cycles
Duration - Up to 36 months
Participants are monitored for disease status, survival, quality of life, and side effects for up to 36 months after treatment.
Regular follow-up visits at defined intervals
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
L M Spring, S M Tolaney, G Fell...
https://pubmed.ncbi.nlm.nih.gov/38092228/Massachusetts General Hospital
Lead Sponsor
Gilead Sciences
Collaborating Sponsor